Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prodrugs].

J F Giudicelli1

  • 1Service de Pharmacologie clinique, Hôpital de Bicêtre, Le Kremlin-Bicêtre.

Presse Medicale (Paris, France : 1983)
|May 25, 1988
PubMed
Summary
This summary is machine-generated.

Prodrugs are inactive compounds transformed into active drugs within the body. They overcome challenges in drug delivery, absorption, and targeting for improved therapeutic outcomes.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2005
Same author

Coronary dilatation reserve in experimental hypertension and chronic heart failure: effects of blockade of the renin-angiotensin system.

Clinical and experimental pharmacology & physiology·2002
Same author

Pharmacological delayed preconditioning against ischaemia-induced ventricular arrhythmias: effect of an adenosine A(1)-receptor agonist.

British journal of pharmacology·2001
Same author

Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning.

The Journal of pharmacology and experimental therapeutics·2001
Same author

Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.

Journal of cardiac failure·2001
Same author

Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients.

British journal of clinical pharmacology·2001
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Drug Delivery Systems

Context:

  • Traditional drugs face limitations like poor solubility, stability, and targeted delivery.
  • Overcoming pharmacokinetic and pharmacodynamic barriers is crucial for effective drug therapy.

Purpose:

  • To elucidate the role and mechanisms of prodrugs in pharmaceutical science.
  • To highlight how prodrug strategies address inherent drug limitations.

Summary:

  • Prodrugs are inert precursors converted in vivo to active therapeutic agents.
  • They are designed to solve pre-administration (solubilization, stability), in vivo (absorption, distribution), and targeting issues.
  • Key prodrug types and their solution mechanisms are discussed.

Impact:

  • Prodrugs enhance drug efficacy and safety by improving delivery and targeting.
  • This strategy expands therapeutic options for challenging medical conditions.
  • Advances in prodrug design offer innovative solutions in drug development.